Response Pharmaceuticals

Executive Summary

Response Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule therapies for weight management and metabolic health, with a focus on high-need populations such as patients experiencing antipsychotic-induced weight gain. Founded in 2018 and based in San Diego, the company's lead candidate, RDX-002, is an oral intestinal microsomal triglyceride transfer protein (MTP) inhibitor designed to reduce fat absorption and improve metabolic parameters. RDX-002 is currently in Phase 2 clinical trials targeting individuals on antipsychotic medications, a population with limited therapeutic options for weight gain. Addressing this unmet need is critical, as weight gain and metabolic dysregulation significantly impact patient compliance and overall health outcomes. The company's approach leverages a well-validated mechanism with a novel application, potentially offering a differentiated and safer alternative to existing weight management drugs. While Response is still private and early-stage, its specialized focus on a niche but sizable market positions it for potential growth pending successful clinical data and strategic partnerships.

Upcoming Catalysts (preview)

• H2 2026Phase 2 Top-Line Data Readout for RDX-00255% success
• 2026Series B or Strategic Partnership Announcement60% success